首页> 美国卫生研究院文献>Cancer Science >Microribonucleic acids and gastric cancer
【2h】

Microribonucleic acids and gastric cancer

机译:微生物核酸和胃癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Gastric carcinogenesis is a multistep process involving genetic and epigenetic alteration of protein‐coding proto‐oncogenes and tumor‐suppressor genes. Microribonucleic acids (miR) are a recently‐described class of genes encoding small non‐coding RNA molecules, which primarily act by downregulating the translation of target mRNA. It has become apparent that miR are also key factors in cancer, playing both oncogenic and tumor‐suppressing roles in gastric cancer. Recent studies have shown that a substantial number of miR show differential expression in gastric cancer tissues, and they are turning out to be just like any other regulatory gene. In this connection, miR dysregulation are reported to be associated with incidence, early diagnosis and prognosis of gastric cancer. Therefore, investigation of the biological aspects of miR dysregulation might help us better understand the pathogenesis of gastric cancer and promote the development of miR‐directed therapeutics against this deadly disease. The aim of the present review was to describe the mechanisms of several known miR, summarize recent studies on oncogenic miR (e.g. miR‐21, miR‐106a and miR‐17), tumor suppressor miR (e.g. miR‐101, miR‐181, miR‐449, miR‐486, let‐7a) and controversial roles of miR (e.g. miR‐107, miR‐126) for gastric cancer. In addition, their potential clinical applications and prospects in gastric cancer, such as biomarkers and clinical therapy tools, are also briefly discussed. (Cancer Sci 2012; 103: 620–625)
机译:胃癌发生涉及蛋白质编码的原子癌和肿瘤抑制基因的遗传和表观遗传改变的多步骤。微生核糖核酸(MIR)是编码小型非编码RNA分子的最近描述的基因,其主要通过下调靶mRNA的翻译。显而易见的是,MIR也是癌症的关键因素,在胃癌中发挥致癌和肿瘤抑制作用。最近的研究表明,大量的MIR在胃癌组织中显示出差异表达,并且它们正常就像任何其他调节基因一样。在这方面,据报道,MIR呼吸缺乏测定与胃癌的发病,早期诊断和预后有关。因此,对miR失呼扫描的生物方面的调查可能有助于我们更好地了解胃癌的发病机制,促进MIR针对这种致命疾病的MIR导向治疗的发病机制。本综述的目的是描述若干已知的MIR的机制,总结了近期对致癌MIR的研究(例如MIR-21,MIR-106A和MIR-17),肿瘤抑制MIR(例如MIR-101,MIR-181, miR-449,miR-486,Let-7a)和MiR(例如miR-107,miR-126)用于胃癌的争议作用。此外,还简要讨论了它们潜在的临床应用和胃癌的前景,例如生物标志物和临床治疗工具。 (癌症SCI 2012; 103:620-625)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号